Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental antibody cocktail offers hope for rabies patients with no other options

NCT ID NCT07706907

Disease control Sponsor: Synermore Biologics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This program provides access to SYN023, a combination of two lab-made antibodies (zamerovimab and mazorelvimab) designed to neutralize the rabies virus. It is for people in the United States with confirmed or suspected life-threatening rabies who cannot join other studies or access approved treatments. The antibodies are given alongside standard rabies care, and the goal is to offer a potential treatment when no alternatives exist.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dual monoclonal antibody cocktail (zamerovimab and mazorelvimab) targeting the rabies virus
What this could lead to
If effective, this could provide a new treatment option for people with life-threatening rabies, a disease that is almost always fatal once symptoms appear.
What could go wrong
This is an expanded access program, not a formal trial, so evidence of benefit is limited. Rabies is extremely difficult to treat, and the antibodies may not change the outcome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be ineligible for or lack access to other investigational or approved therapies * Must have no available alternative curative treatment options Exclusion Criteria: No standardized universal exclusion criteria are predefined for this Expanded Access Program. \- Clinical contraindications identified on an individual basis by the treating critical care clinician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rabies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rabies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.